Enantioselective formal total synthesis of the antitumor macrolide bryostatin 7

Organic Letters

Volumn 8, Issue 20, 2006, Pages 4477-4480

  Manaviazar, Soraya ^a   Frigerio, Mark ^a   Bhatia, Gurpreet S ^a   Hummersone, Marc G ^a   Aliev, Abil E ^a   Hale, Karl J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRYOSTATIN; BRYOSTATIN 7; MACROLIDE;

ARTICLE; CHEMISTRY; STEREOISOMERISM; SYNTHESIS;

ANTINEOPLASTIC AGENTS; BRYOSTATINS; MACROLIDES; STEREOISOMERISM;

EID: 33750037020     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol061626i     Document Type: Article

References (43)

1. Bryostatin 1 isolation and structure determination: Pettit, G. R.; Herald, C. L.; Clarity, J.; Arnold, E.; Doubek, D. L.; Herald, D. L. J. Am. Chem. Soc. 1982, 104, 6848.
2. For reviews on bryostatin chemistry and biology, see: (a) Norcross, R.; Paterson, I. Chem. Rev. 1995, 95, 2041.
3. (b) Mutter, R.; Wills, M. Bioorg. Med. Chem. 2000, 8, 1841.
4. (c) Hale, K. J.; Hummersone, M. G.; Manaviazar, S.; Frigerio, M. Nat. Prod. Rep, 2002, 413.
5. Bryostatin 20: Lopanik, N.; Gustafson, K. R.; Lindquist, N. J. Nat. Prod. 2004, 67, 1412.
6. Mendola, D. In Drugs from the Sea; Fusetani, N., Ed.; Karger: Basel, 2000; p 20.
7. Some phase II human clinical trials include: (a) Madhusan, S.; Protheroe, A.; Propper, D.; Han, C.; Corrie, P.; Earl, H.; Hancock, B.; Vasey, P.; Turner, A.; Balkwill, F.; Hoare, S.; Harris, A. L. Br. J. Cancer 2003, 89, 1418.
8. (b) Brockstein, B.; Samuels, B.; Humerickhouse, R.; Arietta, R.; Fishkin, P.; Wade, J.; Sosman, J.; Vokes, E. E. Invest. New Drugs 2001, 19, 249.
9. (c) Pagliaro, L.; Daliani, D.; Amato, R.; Tu, S.-M.; Jones, D.; Smith, T.; Logothetis, C.; Millikan, R. Cancer 2000, 89, 615.
10. (a) Etcheberrigaray, R.; Tan, M.; Dewachter, I.; Kuiperi, C.; Van der Auwera, I.; Wera, S.; Qiao, L.; Bank, B.; Nelson, T. J.; Kozikowski, A. P.; Leuven, F.; Alkon, D. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11141.
11. (b) Sun, M.-K.; Alkon, D. L. Eur. J. Pharmacol. 2005, 512, 43.
12. (a) Total synthesis of bryostatin 7: Kageyama, M.; Tamura, T.; Nantz, M. H.; Roberts, J. C.; Somfai, P.; Whritenour, D. C.; Masamune, S. J. Am. Chem. Soc. 1990, 112, 7407.
13. (b) Masamune, S. Pure. Appl. Chem. 1988, 60, 1587.
14. Total synthesis of bryostatin 2: Evans, D. A.; Carter, P. H.; Carreira, E. M.; Prunet, J. A.; Charette, A. B.; Lautens, M. Angew. Chem., Int. Ed. Engl. 1998, 37, 2354.
15. Total synthesis of bryostatin 3: Ohmori, K.; Ogawa, Y.; Obitsu, T.; Ishikawa, Y.; Nishiyama, S.; Yamamura, S. Angew. Chem., Int. Ed. 2000, 39, 2290.
16. (a) Hale, K. J.; Frigerio, M.; Manaviazar, S. Org. Lett. 2003, 5, 503.
17. (b) Hale, K. J.; Frigerio, M.; Manaviazar, S. Org. Lett. 2001, 3, 3791.
18. (c) Hale, K. J.; Lennon, J. A.; Manaviazar, S.; Javaid, M. H.; Hobbs, C. J. Tetrahedron Lett. 1995, 36, 1359.
19. (d) Hale, K. J.; Hummersone, M. G.; Bhatia, G. S. Org. Lett. 2000, 2, 2189.
20. For recent work on BC analogue construction, see: (a) Hale, K. J.; Frigerio, M.; Manaviazar, S.; Hummersone, M. G.; Fillingham, I.; Barsukov, I.; Damblon, C.; Gescher, A.; Roberts, G. C. K. Org. Lett. 2003, 5, 499.
21. (b) Keck, G. E.; Truong, A. P. Org. Lett. 2005, 7, 2149.
22. For some other recent analogue work, see: (a) Wender, P. A.; Clarke, M. O.; Horan, J. C. Org. Lett. 2005, 7, 1995.
23. (b) Wender, P. A.; Verma, V. A. Org. Lett. 2006, 8, 1893 and the references therein.
24. For other dithiane alkylation strategies for constructing the C(9)-C(10) bond of the bryostatins, see: (a) Vakalopoulos, A.; Lampe, T. F. J.; Hoffmann, H. M. R. Org. Lett. 2001, 3, 929.
25. (b) Ref 9.
26. (a) Chapleur, Y. Chem. Commun. 1983, 141.
27. (b) Hong, C. Y.; Kishi, Y. J. Am. Chem. Soc. 1991, 113, 9693.
28. (c) Generally, we have found it more convenient and far less sacrificial to conduct this C-methylation with ketone 9 that has only been recrystallized twice. Generally, two recrystallizations provide material that is approximately 90% pure; the other main contaminant appears to be 1-phenylpentan-2-ol.
29. Barton, D. H. R.; Motherwell, W. B.; Stange, A. Synthesis 1981, 743.
30. (a) Kocienski, P.; Narquizian, R.; Raubo, P.; Smith, C.; Farrugia, L. J.; Muir, K.; Boyle, F. T. J. Chem. Soc., Perkin Trans. 1 2000, 2357.
31. 3 reagent with the anomeric OMe would also favor delivery of hydride to the underside of 8 to give 15, but a referee has argued against this proposal on the basis that, if it did occur, it would most likely cause loss of the acid-labile C(9)-OMe.
32. Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P. Synthesis 1994, 639.
33. Blakemore, P. R.; Cole, W. J.; Kocienski, P. J.; Morley, A. Synlett 1998, 26.
34. Hale, K. J.; Domostoj, M. M.; Tocher, D. A.; Irving, E.; Scheinmann, F. Org. Lett. 2003, 5, 2927.
35. Evans, D. A.; Gage, J. R. J. Org. Chem. 1992, 57, 1958.
36. Smith, A. B., III; Chen, K.; Robinson, D. J.; Laakso, L. M.; Hale, K. J. Tetrahedron Lett. 1994, 35, 4271.
37. For other recent approaches to the AB region of the bryostatins, see: (a) Voight, E. A.; Seradj, H.; Roethle, P. A.; Burke, S. D. Org. Lett. 2004, 6, 4045.
38. (b) Ball, M.; Baron, A.; Bradshaw, B.; Omori, H.; MacCormick, S.; Thomas, E. J. Tetrahedron Lett. 2004, 45, 8737.
39. (c) Keck, G. E.; Truong, A. P. Org. Lett. 2005, 7, 2153.
40. (d) Ball, M.; Bradshaw, B. J.; Dumeunier, R.; Gregson, T. J.; MaeCormick, S.; Omuri, H.; Thomas, E. J. Tetrahedron Lett. 2006, 47, 2223.
41. (e) Keck, G. E.; Welch, D. S.; Vivian, P. K. Org. Lett. 2006, 8, 3667.
42. (f) For earlier work, see: ref 2c.
43. (g) For some other recent relevant work on the B-ring, see: Trost, B. M.; Yang, H.; Wuitschik, G. Org. Lett. 2005, 7, 4761.